Tag: Race Oncology

New Race non-executive director Dr John Cullity has used his first interview to highlight the company’s growth potential.

In a major development for the Australian biotech sector, ASX-listed oncology drug developer, Viralytics, has been sold to US-based big pharma, Merck, for US$502 million. As a former Director of Viralytics from 2008 – 2014, current Race Oncology Managing Director…

Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and…

Race Oncology has released its Investor Presentation ahead of CEO Peter Molloy’s address at the BIO CEO Conference in New York City.

A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs…

Swiss biotech company TargImmune is announcing a new international research collaboration with Australia’s oldest medical research institute, the Walter and Eliza Hall Institute, to progress the development of a cutting-edge cancer immunotherapy platform. Building on the expertise of Professor Alexander…

In November 2017, Race CEO Peter Molloy spoke to investors in London at the Biotech & Money conference.